DrugBiological
Factor IX Fc fusion protein clinical trials
Also written Alprolix, BIIB029 and rFIXFc.
- studies test it
- 5
- open now
- 0
- in phase 3
- 3
- first study started
- 2008
How studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
5 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 1
Bioverativ Therapeutics Inc. (3) · Bioverativ, a Sanofi company (1) · Emory University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses factor IX Fc fusion protein is read from its arms, and is right about nine times in ten.
Testing it · 5
- Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia BCompletedPhase 3Bioverativ, a Sanofi companyNCT02234310Written as rFIXFc
- Phase I/IIa Study of FIXFc in Hemophilia B PatientsCompletedPhase 1Bioverativ Therapeutics Inc.NCT00716716Written as rFIXFc
- Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BCompletedPhase 3Bioverativ Therapeutics Inc.NCT01440946Written as rFIXFc
- Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia BCompletedPhase 3Bioverativ Therapeutics Inc.NCT01425723Written as rFIXFc
- Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia CarriersCompletedEarly Phase 1Emory UniversityNCT03272568Written as Recombinant FIX Fc fusion product Alprolix